These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36226470)

  • 61. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
    Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
    Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cutaneous squamous cell carcinoma presenting with facial paralysis: good response to Cemiplimab.
    Estenaga A; Castañón E; García-Martínez FJ; Redondo P
    J Dtsch Dermatol Ges; 2021 Mar; 19(3):448-450. PubMed ID: 32930485
    [No Abstract]   [Full Text] [Related]  

  • 63. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
    Eglmeier J; Debus D; Schultz ES
    Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
    [No Abstract]   [Full Text] [Related]  

  • 64. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
    Villani A; Potestio L; Fabbrocini G; Scalvenzi M
    Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
    Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
    Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
    Giri A; Bauman JR
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department.
    Guillaume T; Puzenat E; Popescu D; Aubin F; Nardin C
    Br J Dermatol; 2021 Nov; 185(5):1056-1058. PubMed ID: 34107076
    [No Abstract]   [Full Text] [Related]  

  • 69. A Case of Miller Fisher Syndrome Due to the Use of Cemiplimab.
    Ghosh A; Harish Bindiganavile S; Bhat N; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):e343-e345. PubMed ID: 32868575
    [No Abstract]   [Full Text] [Related]  

  • 70. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
    Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
    Patel R; Chang ALS
    Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
    Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
    JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
    Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
    J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma.
    Shalhout SZ; Park JC; Emerick KS; Sullivan RJ; Kaufman HL; Miller DM
    J Am Acad Dermatol; 2021 Oct; 85(4):1038-1040. PubMed ID: 33476726
    [No Abstract]   [Full Text] [Related]  

  • 75. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma.
    Miller K; Sherman W; Ratner D
    Dermatol Surg; 2010 Dec; 36(12):2069-74. PubMed ID: 21044226
    [No Abstract]   [Full Text] [Related]  

  • 76. Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis.
    Marzano AV; Raimondo MG; Berti E; Meroni PL; Ingegnoli F
    Clin Rev Allergy Immunol; 2017 Dec; 53(3):428-438. PubMed ID: 28578472
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Multimodality Therapy for Locally Advanced Cutaneous Squamous Cell Carcinoma].
    Garzarolli M; Bota O; Meinhardt M; Juratli T; Meier F
    Laryngorhinootologie; 2023 Aug; 102(8):612-615. PubMed ID: 36395785
    [No Abstract]   [Full Text] [Related]  

  • 78. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM; D'Cruz DP
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multiple keratin granulomata: A potential histologic clue to cutaneous squamous cell carcinoma responding to programmed cell death protein 1 inhibitor therapy.
    Kahn BJ; Parker D; Yushak M; Stoff B; Blalock TW
    J Cutan Pathol; 2019 Jun; 46(6):452-454. PubMed ID: 30811629
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?
    Soura E; Gagari E; Stratigos A
    Curr Opin Oncol; 2019 Sep; 31(5):461-468. PubMed ID: 31394558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.